Shares of Clarivate PLC (CLVT) have gained 1.6% over the past four weeks to close the last trading session at $5.08, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $6.56 indicates a potential upside of 29.1%.The average comprises eight short-term price targets ranging from a low of $4 to a high of $8, with a standard deviation of $1.45. While the lowest estimate indicates a dec ...

Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON, Jan. 16, 2025 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated 2024 Year in Review series. This multipart special report offers an in-depth analysis of the therapeutic trends, regulatory actions and economic shifts that defined biopharma, med tech and scientific innovation over the past year while fo ...

Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Post-marketing Pharmacovigilance and Medical Information Market by Type by Service, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering.The global post-marketing pharmacovigilance and medical information market size was estimated to be USD 6.22 billion in 2023 and is expected to reach USD 16.99 billion by 2034 with a CAGR of 9.56% during the forecast period 2024-2034. The market will grow as a result of factors such as rising ...

New modular analytics solution empowers commercial teams to optimize strategies and improve patient outcomes LONDON, Jan. 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of DRG Fusion, an innovative platform to support commercial analytics in life sciences. Powered by integrated real-world data and built by clinical and data science experts, Fusion provides biopharma and medtech organizations with the tools to understan ...

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to redefine the future of healthcare. This year, the highly anticipated resource highlights 11 drugs projected to achieve blockbuster status or revolutionize treat ...

Core Viewpoint - Clarivate Plc has announced a new share repurchase program of up to $500 million for a two-year period from January 1, 2025, to December 31, 2026, replacing the current program which ends on December 31, 2024 [1][2]. Group 1: Share Repurchase Program - The new share repurchase program will allow the company to buy back its ordinary shares through open-market purchases [1][3]. - The previous share repurchase program resulted in the repurchase of $300 million of ordinary shares, with $200 million repurchased in the third and fourth quarters of 2024 [2]. - The new program reflects the Board's confidence in the company's growth and financial performance, aligning with its Value Creation Plan [3]. Group 2: Financial Management - Clarivate has prepaid $75 million of term-loan debt in the fourth quarter of 2024, totaling $133 million in prepayments for the year [2]. - The company emphasizes a balanced approach to capital allocation, which includes returning capital to shareholders and reducing debt [3]. Group 3: Operational Flexibility - The new share repurchase program does not obligate Clarivate to repurchase a specific dollar amount or number of shares and can be modified or terminated at any time [3]. - The company will conduct open-market purchases based on market conditions, availability of shares, and other factors at management's discretion [3].

Faster and more relevant results to empower critical IP decision-making LONDON, Dec. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of AI Search in Derwent™. Combining artificial intelligence (AI) with the premier source of global patent data, Derwent World Patents Index (DWPI)™, this solution will enable intellectual property (IP) professionals to make reliable innovation decisions by finding more relevant patents in ...

Revealing highly active specialties in sciences and social sciencesLONDON, Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, and the Chinese Academy of Sciences (CAS) today released 2024 Research Fronts™, identifying the most dynamic and rapidly growing specialties in sciences and social sciences. This marks the eleventh annual collaboration between the two organizations, with the report launched at a ceremony held in Beijing today.The report ...

New seven-part series explores disparities in care, funding and innovation impacting half the world's populationLONDON, Nov. 21, 2024 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has launched its new special series, 'Healing the Health Divide.' This seven-part series sheds light on the persistent disparities in women's health research, funding, and treatment.Women make up half of the global population, yet their health remains co ...

Prioritizing research integrity with enhanced filters to address publication and citation manipulation LONDON, Nov. 19, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today revealed its 2024 list of Highly Cited Researchers™ – influential researchers at universities, research institutes and commercial organizations around the world who have demonstrated significant and broad influence in their field(s) of research. Analysts at the Institute for Scie ...